Blog
About

10
views
0
recommends
+1 Recommend
1 collections
    8
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Combination of Gemcitabine and Docetaxel in Management of Leiomyosarcoma Metastasis

      Journal of Medical Research and Innovation

      Biomedical Research and Therapy

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Leiomyosarcoma is a type of a soft tissue sarcoma which is one of the rarest tumor found in the human mankind. It is predominantly localized either in stomach, small intestine or retroperitoneum and often metastasizes to the distant parts like the lungs or liver. The main route of the metastasis is via the bloodstream, however, the lymphatics could also be used as a medium. The etiology of leiomyosarcoma (LMS) is yet unknown to men, but few studies has shown that genetic factors have an important role to play. The treatment options available for LMS metastasis (mets) in liver are very limited which ranges from chemotherapy, radiofrequency ablation and target therapy. Here I discuss a case of LMS mets to the liver managed by a combination therapy of Gemcitabine and Docetaxel.

          Related collections

          Author and article information

          Journal
          Journal of Medical Research and Innovation
          J Med Res Innov
          Biomedical Research and Therapy
          2456-8139
          May 11 2017
          April 14 2017
          : 1
          : 2
          : AY1-AY2
          Article
          10.15419/jmri.31
          © 2017

          http://creativecommons.org/licenses/by-nc/4.0

          Comments

          Comment on this article